Does pre-treatment with ACE inhibitors improve the acute success of electrical cardioversion and prevent subacute recurrences in patients with persistent atrial fibrillation?
Pre-treatment with ACE inhibitors improves the acute success rate of electrical cardioversion in persistent atrial fibrillation but does not prevent subacute recurrences at 1 month.
BACKGROUND: Persistent atrial fibrillation (AF) is difficult to treat. In the absence of class I or III antiarrhythmic drugs sinus rhythm is maintained in only 30% of patients during the first year after electrical cardioversion (ECV). One of the remodeling processes induced by AF is fibrosis, which relates to inducibility and maintenance of AF. The renin-angiotensin system may play a important role in this. The aim of this study was to investigate the role of angiotensin-converting enzyme (ACE) inhibitor use on efficacy of ECV, and occurrence of subacute recurrences. METHODS: One hundred-seven consecutive patients with persistent AF underwent ECV. In twenty-eight (26%) patients ACE inhibitors had been started before initiation of the present episode of AF ('pre-treated' patients). RESULTS: ECV was successful in 96% of patients who were on ACE inhibitors before start of the present episode of AF compared to 80% of the patients not pre-treated (p = 0.04). After 1 month of follow-up 49% of the pre-treated patients and 50% of those not pre-treated with ACE inhibition were still in sinus rhythm (p=ns). Multivariate analysis showed that pre-treatment with ACE inhibitors and a smaller left atrial size were independent predictors of successful ECV (OR = 5.8, C.I. 1.3-26.1, and OR = 5.6, C.I. 1.2-25.3, respectively). CONCLUSIONS: Pre-treatment with ACE inhibitors may improve acute success of ECV but does not prevent AF recurrences.
Noord et al. (Mon,) studied this question.